|
Variables
|
Validation cohort(n = 156)
|
derivation cohort (n = 421)
|
P value
|
|---|
|
Age (years)
|
48.92 ± 11.94
|
47.93 ± 11.40
|
0.372
|
|
Gender (M: F)
|
129/27
|
365/56
|
–
|
|
Cirrhosis (%)
|
114(73.1%)
|
299(71.02%)
|
0.627
|
|
Bacterial infections
|
101(64.74%)
|
307(72.92%)
|
0.055
|
|
TBIL (μmol/L)
|
239.43 ± 136.17
|
323.39 ± 165.69
|
< 0.001
|
|
INR
|
1.92(1.58, 2.43)
|
2.25(1.86, 2.76)
|
< 0.001
|
|
Cr (μmol/L)
|
62.40(52.15, 80.35)
|
69.30(57.28, 87.90)
|
0.004
|
|
RDW (%)
|
16.10(14.50, 18.10)
|
15.90(14.38, 18.42)
|
0.842
|
|
MPV (FL)
|
11.29 ± 1.67
|
11.74 ± 1.53
|
0.003
|
|
NLR
|
4.33(2.68, 7.87)
|
4.84(3.19, 8.07)
|
< 0.001
|
|
MLR
|
0.61(0.41, 0.90)
|
0.64(0.42, 0.94)
|
0.473
|
|
GPR
|
0.91(0.53, 1.50)
|
0.97(0.59, 1.69)
|
0.162
|
|
RPR
|
0.17(0.11, 0.28)
|
0.19(0.12, 0.30)
|
0.093
|
|
MPR
|
0.70(0.59, 0.83)
|
0.14(0.09, 0.20)
|
< 0.001
|
|
PNI
|
35.03(30.65, 41.10)
|
34.10(30.20, 38.31)
|
0.033
|
|
PLR
|
95.92(63.99, 143.22)
|
91.03(62.69, 127.69)
|
0.206
|
|
RLR
|
17.77(11.73, 26.73)
|
16.70(3.71, 85.81)
|
0.939
|
|
MELD SCORE
|
21.41 ± 7.84
|
25.05 ± 6.75
|
< 0.001
|
|
MELD-Na
|
21.24 ± 15.66
|
24.32 ± 12.69
|
0.001
|
|
CTP
|
10.48 ± 1.89
|
11.09 ± 2.00
|
0.029
|
- TBIL total bilirubin, ALB albumin, γ-GGT gamma-glutamyl transpeptidase, Cr creatinine, Cyst-c Cystatin c, Serum Na + serum sodium, PT prothrombin time, INR international normalized ratio, PTA prothrombin activity, WBC white blood cell count, RDW red blood cell distribution width, NLR neutrophil/lymphocyte ratio, MLR monocyte/lymphocyte ratio, PLR platelet/lymphocyte ratio, RPR RDW/platelet ratio, GPR gamma-glutamyl transpeptidase/platelet ratio, MPV mean platelet volume, RLR RDW/lymphocyte ratio, PNI prognostic nutritional index, MPR MPV/platelet ratio, MELD model for end-stage liver disease, MELD-Na MELD-sodium score, CTP child-Turcotte Pugh score
